Login

Markus Carlson

ORCID: 0000-0002-4924-0625
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5034178813
Research Areas
  • HER2/EGFR in Cancer Research
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Cells and Metastasis
  • Melanoma and MAPK Pathways
  • Cell Adhesion Molecules Research

Seagen (United States)
 2023

 SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
OPENALEX - Publications 
Rebecca Mazahreh Marsha L. Mason John J. Gosink Devra Olson Robert Thurman and 19 more Christopher Hale Lori Westendorf Thomas A. Pires Christopher I. Leiske Markus Carlson Liem T. Nguyen Julia H. Cochran Nicole M. Okeley Roma Yumul Steven Jin Ivan J. Stone Disha Sahetya Albina Nesterova Sean Allred Kelly Hensley Rachael Hu Robert Lawrence Timothy S. Lewis Sharsti Sandall

SGN-CD228A is an investigational antibody-drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. consists of humanized antibody, hL49, with high specificity and affinity for CD228 that stably conjugated 8 molecules the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via novel glucuronide linker. We performed comprehensive IHC studies, which corroborated published RNA sequencing data...

10.1158/1535-7163.mct-22-0401 article EN cc-by-nc-nd Molecular Cancer Therapeutics 2023-02-07
 Supplementary Methods from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
OPENALEX - Publications 
Rebecca Mazahreh Marsha L. Mason John J. Gosink Devra Olson Robert Thurman and 19 more Christopher Hale Lori Westendorf Thomas A. Pires Christopher I. Leiske Markus Carlson Liem T. Nguyen Julia H. Cochran Nicole M. Okeley Roma Yumul Steven Jin Ivan J. Stone Disha Sahetya Albina Nesterova Sean Allred Kelly Hensley Rachael Hu Robert Lawrence Timothy S. Lewis Sharsti Sandall

<p>Antibody humanization, binding assays, conjugation, mass spec, additional in vivo details</p>

10.1158/1535-7163.22495327 preprint EN cc-by 2023-04-03
 Supplementary Figures from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
OPENALEX - Publications 
Rebecca Mazahreh Marsha L. Mason John J. Gosink Devra Olson Robert Thurman and 19 more Christopher Hale Lori Westendorf Thomas A. Pires Christopher I. Leiske Markus Carlson Liem T. Nguyen Julia H. Cochran Nicole M. Okeley Roma Yumul Steven Jin Ivan J. Stone Disha Sahetya Albina Nesterova Sean Allred Kelly Hensley Rachael Hu Robert Lawrence Timothy S. Lewis Sharsti Sandall

<p>Figures S1-S9</p>

10.1158/1535-7163.22495330 preprint EN cc-by 2023-04-03
 Supplementary Figures from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
OPENALEX - Publications 
Rebecca Mazahreh Marsha L. Mason John J. Gosink Devra Olson Robert Thurman and 19 more Christopher Hale Lori Westendorf Thomas A. Pires Christopher I. Leiske Markus Carlson Liem T. Nguyen Julia H. Cochran Nicole M. Okeley Roma Yumul Steven Jin Ivan J. Stone Disha Sahetya Albina Nesterova Sean Allred Kelly Hensley Rachael Hu Robert Lawrence Timothy S. Lewis Sharsti Sandall

<p>Figures S1-S9</p>

10.1158/1535-7163.22495330.v1 preprint EN cc-by 2023-04-03
 Data from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
OPENALEX - Publications 
Rebecca Mazahreh Marsha L. Mason John J. Gosink Devra Olson Robert Thurman and 19 more Christopher Hale Lori Westendorf Thomas A. Pires Christopher I. Leiske Markus Carlson Liem T. Nguyen Julia H. Cochran Nicole M. Okeley Roma Yumul Steven Jin Ivan J. Stone Disha Sahetya Albina Nesterova Sean Allred Kelly Hensley Rachael Hu Robert Lawrence Timothy S. Lewis Sharsti Sandall

<div>Abstract<p>SGN-CD228A is an investigational antibody–drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. SGN-CD228A consists of humanized antibody, hL49, with high specificity and affinity for CD228 that stably conjugated 8 molecules the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via novel glucuronide linker. We performed comprehensive IHC studies, which...

10.1158/1535-7163.c.6534823.v1 preprint EN 2023-04-03
 Data from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
OPENALEX - Publications 
Rebecca Mazahreh Marsha L. Mason John J. Gosink Devra Olson Robert Thurman and 19 more Christopher Hale Lori Westendorf Thomas A. Pires Christopher I. Leiske Markus Carlson Liem T. Nguyen Julia H. Cochran Nicole M. Okeley Roma Yumul Steven Jin Ivan J. Stone Disha Sahetya Albina Nesterova Sean Allred Kelly Hensley Rachael Hu Robert Lawrence Timothy S. Lewis Sharsti Sandall

<div>Abstract<p>SGN-CD228A is an investigational antibody–drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. SGN-CD228A consists of humanized antibody, hL49, with high specificity and affinity for CD228 that stably conjugated 8 molecules the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via novel glucuronide linker. We performed comprehensive IHC studies, which...

10.1158/1535-7163.c.6534823 preprint EN 2023-04-03
 Supplementary Methods from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
OPENALEX - Publications 
Rebecca Mazahreh Marsha L. Mason John J. Gosink Devra Olson Robert Thurman and 19 more Christopher Hale Lori Westendorf Thomas A. Pires Christopher I. Leiske Markus Carlson Liem T. Nguyen Julia H. Cochran Nicole M. Okeley Roma Yumul Steven Jin Ivan J. Stone Disha Sahetya Albina Nesterova Sean Allred Kelly Hensley Rachael Hu Robert Lawrence Timothy S. Lewis Sharsti Sandall

<p>Antibody humanization, binding assays, conjugation, mass spec, additional in vivo details</p>

10.1158/1535-7163.22495327.v1 preprint EN cc-by 2023-04-03
 Supplementary Figures from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
OPENALEX - Publications 
Rebecca Mazahreh Marsha L. Mason John J. Gosink Devra Olson Robert Thurman and 19 more Christopher Hale Lori Westendorf Thomas A. Pires Christopher I. Leiske Markus Carlson Liem T. Nguyen Julia H. Cochran Nicole M. Okeley Roma Yumul Steven Jin Ivan J. Stone Disha Sahetya Albina Nesterova Sean Allred Kelly Hensley Rachael Hu Robert Lawrence Timothy S. Lewis Sharsti Sandall

<p>Figures S1-S9</p>

10.1158/1535-7163.22551999.v1 preprint EN cc-by 2023-04-04
 Supplementary Methods from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
OPENALEX - Publications 
Rebecca Mazahreh Marsha L. Mason John J. Gosink Devra Olson Robert Thurman and 19 more Christopher Hale Lori Westendorf Thomas A. Pires Christopher I. Leiske Markus Carlson Liem T. Nguyen Julia H. Cochran Nicole M. Okeley Roma Yumul Steven Jin Ivan J. Stone Disha Sahetya Albina Nesterova Sean Allred Kelly Hensley Rachael Hu Robert Lawrence Timothy S. Lewis Sharsti Sandall

<p>Antibody humanization, binding assays, conjugation, mass spec, additional in vivo details</p>

10.1158/1535-7163.22551996.v1 preprint EN cc-by 2023-04-04
 Supplementary Figures from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
OPENALEX - Publications 
Rebecca Mazahreh Marsha L. Mason John J. Gosink Devra Olson Robert Thurman and 19 more Christopher Hale Lori Westendorf Thomas A. Pires Christopher I. Leiske Markus Carlson Liem T. Nguyen Julia H. Cochran Nicole M. Okeley Roma Yumul Steven Jin Ivan J. Stone Disha Sahetya Albina Nesterova Sean Allred Kelly Hensley Rachael Hu Robert Lawrence Timothy S. Lewis Sharsti Sandall

<p>Figures S1-S9</p>

10.1158/1535-7163.22551999 preprint EN cc-by 2023-04-04
 Supplementary Methods from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
OPENALEX - Publications 
Rebecca Mazahreh Marsha L. Mason John J. Gosink Devra Olson Robert Thurman and 19 more Christopher Hale Lori Westendorf Thomas A. Pires Christopher I. Leiske Markus Carlson Liem T. Nguyen Julia H. Cochran Nicole M. Okeley Roma Yumul Steven Jin Ivan J. Stone Disha Sahetya Albina Nesterova Sean Allred Kelly Hensley Rachael Hu Robert Lawrence Timothy S. Lewis Sharsti Sandall

<p>Antibody humanization, binding assays, conjugation, mass spec, additional in vivo details</p>

10.1158/1535-7163.22551996 preprint EN cc-by 2023-04-04
 Data from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
OPENALEX - Publications 
Rebecca Mazahreh Marsha L. Mason John J. Gosink Devra Olson Robert Thurman and 19 more Christopher Hale Lori Westendorf Thomas A. Pires Christopher I. Leiske Markus Carlson Liem T. Nguyen Julia H. Cochran Nicole M. Okeley Roma Yumul Steven Jin Ivan J. Stone Disha Sahetya Albina Nesterova Sean Allred Kelly Hensley Rachael Hu Robert Lawrence Timothy S. Lewis Sharsti Sandall

<div>Abstract<p>SGN-CD228A is an investigational antibody–drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. SGN-CD228A consists of humanized antibody, hL49, with high specificity and affinity for CD228 that stably conjugated 8 molecules the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via novel glucuronide linker. We performed comprehensive IHC studies, which...

10.1158/1535-7163.c.6534823.v2 preprint EN 2023-04-04
Coming Soon ...